Evidence map›Paper›PMID 40577260›Full record

ArticleJapanese journal of clinical oncology2025

Predictive ability of the geriatric 8 screening tool for treatment completion of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin therapy in patients with urothelial carcinoma.

Yoshiaki Kurokawa, Taketo Kawai, Satoru Taguchi, Kazuki Honda, Kazuki Maki, Yoshiki Ambe, Naoki Saegusa, Masahiro Yamamoto, Yuumi Tokura, Kazuki Yanagida and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Japanese journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Yoshiaki KurokawaDepartment of Urology, Graduate School of Medicine The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Taketo KawaiDepartment of Urology, Graduate School of Medicine The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.ORCID 0000-0002-7279-2874
Satoru TaguchiDepartment of Urology, Graduate School of Medicine The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.ORCID 0000-0002-1291-4294
Kazuki HondaDepartment of Urology, Graduate School of Medicine The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Kazuki MakiDepartment of Urology, Graduate School of Medicine The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Yoshiki AmbeDepartment of Urology, Graduate School of Medicine The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Naoki SaegusaDepartment of Urology, Graduate School of Medicine The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Masahiro YamamotoDepartment of Urology, Graduate School of Medicine The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Yuumi TokuraDepartment of Urology, Teikyo University School of Medicine 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan.
Kazuki YanagidaDepartment of Urology, Teikyo University School of Medicine 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan.
Kazuki TakeiDepartment of Urology, Teikyo University School of Medicine 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan.
Hazuki InoueDepartment of Urology, Teikyo University School of Medicine 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan.
Takehiro TanakaDepartment of Pharmacy, The University of Tokyo Hospital 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Katsuhiko NaraDepartment of Pharmacy, The University of Tokyo Hospital 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Tomoyuki KanekoDepartment of Urology, Teikyo University School of Medicine 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan.
Yoichi FujiiDepartment of Urology, Graduate School of Medicine The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Jimpei MiyakawaDepartment of Urology, Graduate School of Medicine The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Jun KameiDepartment of Urology, Graduate School of Medicine The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Shigenori KakutaniDepartment of Urology, Graduate School of Medicine The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Aya NiimiDepartment of Urology, Graduate School of Medicine The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Daisuke YamadaDepartment of Urology, Graduate School of Medicine The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Yuta YamadaDepartment of Urology, Graduate School of Medicine The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Tappei TakadaDepartment of Pharmacy, The University of Tokyo Hospital 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Tohru NakagawaDepartment of Urology, Teikyo University School of Medicine 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan.
Haruki KumeDepartment of Urology, Graduate School of Medicine The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.ORCID 0000-0001-9841-0857

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) therapy is expected to provide superior therapeutic efficacy compared to gemcitabine and cisplatin therapy as systemic chemotherapy for urothelial carcinoma. However, its high incidence of adverse events raises concerns about tolerability, particularly in older patients. This study evaluated the utility of the Geriatric 8 (G8) screening tool in patients undergoing dd-MVAC therapy and assessed its association with treatment progress.

methodsA retrospective analysis was conducted on 65 patients with urothelial carcinoma who received dd-MVAC therapy between August 2018 and May 2023, with the goal of completing six treatment cycles. The G8 score was evaluated before treatment initiation, and its association with treatment completion and adverse events was examined.

resultsThe median age of patients was 71 years (range, 43-84 years), with 65% male and 35% female. The median pretreatment G8 score was 13 (range, 7-17). Patients with a G8 score ≥14 demonstrated a significantly higher six-cycle treatment completion rate than those with a G8 score <14 (87% vs. 60%, P = 0.026). The incidence of adverse events did not differ between the groups. Furthermore, among various clinicopathological factors, the G8 score was identified as an independent predictor of six-cycle treatment completion (odds ratio: 0.17, P = 0.021), along with Eastern Cooperative Oncology Group Performance Status.

conclusionPretreatment G8 scores were associated with the treatment completion rates of dd-MVAC therapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellGeriatric AssessmentUrologic NeoplasmsAdultAgedAged, 80 and overCisplatinDoxorubicinFemaleHumansMaleMethotrexateMiddle AgedRetrospective StudiesVinblastineCisplatinDoxorubicinMethotrexateVinblastinedose-dense MVACgeriatric 8treatment completion rateurothelial carcinoma

Identifiers

PMID40577260
PMCPMC12501969

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.